Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 1998

View Archived Issues

Sankyo describes NK1/NK2 antagonists for treating asthma

Japanese lab describes new agents for asthma and inflammation

Deferiprone increases incidence of hepatic fibrosis and fails to control iron in thalassemia major

Eptifibatide treatment reduces incidence of death in acute myocardial infarction and unstable angina

Efficacy of collagen membrane delivery systems for rhBMP-2 in treatment of periodontal defects

Laboratory testing of new, more efficient Toleragen drug completed

First diagnostic kit for the detection of stroke developed by Skye PharmaTech

Elan and Endorex form new company to develop oral vaccines

Viagra and nitrates: a lethal combination

Anergen claims production methods for AnergiX compounds

Pfizer selects LTB4 antagonist for clinical testing

New agents for pancreatitis in early development at Sankyo

More asiatic acid derivatives in development at Dong Kook

Bristol-Myers Squibb discovers novel maxi-K channel openers

Toray reports kappa agonists for treating dermatological disorders

HERS study results now in -- results counter expectations

Disappointing results obtained in phase II/III trial of LU-25-109T

Onconase inhibits cancer cell growth and contributes to apoptosis

Il Yang synthesizes gastric H+/K+-ATPase inhibitors with improved stability

First approval for lamivudine in chronic hepatitis B

Nymox progresses with development of NX-B4221

FDA advisory committee meeting scheduled to review Enbrel BLA

Antiasthma drug candidate enters phase I testing at Pharmacia & Upjohn

Lilly describes promising beta3-adrenoceptor agonist at ACS meeting

ACS news flash: R.W. Johnson investigates thrombin inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...